• Revenue from ordinary activities up 19% to $23.9 million
• Clinical Trials revenue up 27% to $22.7 million
• Net profit before tax up 150% to $5.2 million

Cogstate Ltd reported strong financial results for the half-year ended 31 December 2024. Revenue from ordinary activities increased 19% to $23.9 million, driven by a 27% increase in Clinical Trials revenue to $22.7 million. Net profit before tax was up 150% to $5.2 million. The company's Clinical Trials segment continued to grow, leveraging the adoption of decentralized clinical trial methodologies and expanding capabilities in key therapeutic indications. In the Healthcare segment, the Cognigram system has achieved regulatory clearance in multiple jurisdictions. Total staff expenses decreased 3% to $12.8 million. The company's net assets stood at $44.3 million as of 31 December 2024. Cogstate remains focused on driving growth in its core business areas while exploring new opportunities in the healthcare market.

Cogstate has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.